Knight Therapeutics Inc. (TSX:GUD)
Canada · Delayed Price · Currency is CAD 9.34
-0.50 (-5.08%)
Aug 4, 2026, 4:00 PM EST
Knight Therapeutics Ratios and Metrics
Market cap in millions CAD. Fiscal year is January - December.
Millions CAD. Fiscal year is Jan - Dec.
Total Valuation
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Aug '26 Aug 4, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| 917 | 600 | 534 | 525 | 581 | 624 | |
Market Cap Growth | 50.60% | 12.33% | 1.73% | -9.66% | -6.89% | -8.22% |
Enterprise Value | 843.59 | 582.66 | 441.3 | 439.75 | 501.42 | 515.71 |
Last Close Price | 9.34 | 6.05 | 5.34 | 5.19 | 5.18 | 5.30 |
Price Ratios
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Aug '26 Aug 4, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
PE Ratio | 165.27 | - | 133.50 | - | - | 40.77 |
Forward PE | 91.57 | 201.67 | 157.06 | 79.24 | 95.37 | 82.43 |
PS Ratio | 1.80 | 1.33 | 1.44 | 1.60 | 1.98 | 2.56 |
PB Ratio | 1.16 | 0.78 | 0.67 | 0.70 | 0.70 | 0.74 |
P/TBV Ratio | 2.75 | 2.02 | 1.27 | 1.48 | 1.47 | 1.59 |
P/FCF Ratio | 9.07 | 8.95 | 15.80 | 15.01 | 13.80 | 15.31 |
P/OCF Ratio | 8.65 | 8.70 | 14.72 | 14.61 | 12.92 | 13.99 |
EV Ratios
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Aug '26 Aug 4, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
EV/Sales Ratio | 1.65 | 1.29 | 1.19 | 1.34 | 1.71 | 2.12 |
EV/EBITDA Ratio | 14.67 | 10.75 | 7.29 | 9.26 | 23.24 | 14.70 |
EV/EBIT Ratio | - | - | 59.66 | - | - | - |
EV/FCF Ratio | 8.34 | 8.69 | 13.05 | 12.57 | 11.91 | 12.64 |
Financial Efficiency
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Aug '26 Aug 4, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Debt / Equity Ratio | 0.08 | 0.10 | 0.06 | 0.09 | 0.09 | 0.05 |
Debt / EBITDA Ratio | 1.21 | 1.44 | 0.82 | 1.45 | 3.60 | 1.17 |
Debt / FCF Ratio | 0.69 | 1.16 | 1.46 | 1.98 | 1.85 | 1.00 |
Net Debt / Equity Ratio | -0.07 | -0.02 | -0.12 | -0.11 | -0.10 | -0.13 |
Net Debt / EBITDA Ratio | -1.00 | -0.32 | -1.53 | -1.80 | -3.70 | -3.09 |
Net Debt / FCF Ratio | -0.57 | -0.26 | -2.75 | -2.44 | -1.89 | -2.66 |
Asset Turnover | 0.48 | 0.45 | 0.39 | 0.33 | 0.29 | 0.24 |
Inventory Turnover | 1.99 | 2.09 | 2.02 | 1.90 | 1.89 | 1.99 |
Quick Ratio | 1.45 | 1.39 | 2.26 | 2.20 | 1.87 | 1.99 |
Current Ratio | 2.32 | 2.39 | 3.57 | 3.20 | 2.80 | 2.90 |
Return on Equity (ROE) | -0.42% | -0.69% | 0.56% | -2.14% | -3.58% | -1.81% |
Return on Assets (ROA) | -0.29% | -0.23% | 0.77% | -0.29% | -4.01% | -1.26% |
Return on Invested Capital (ROIC) | -0.42% | -0.32% | 1.08% | -0.41% | -5.55% | -1.98% |
Return on Capital Employed (ROCE) | -0.41% | -0.27% | 0.88% | -0.33% | -4.56% | -1.42% |
Yields
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Aug '26 Aug 4, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Earnings Yield | 0.61% | - | 0.75% | - | - | 2.45% |
FCF Yield | 11.03% | 11.17% | 6.33% | 6.66% | 7.25% | 6.53% |
Buyback Yield / Dilution | 1.86% | 1.84% | 5.61% | 6.46% | 7.73% | 5.65% |
Total Shareholder Return | 1.86% | 1.84% | 5.61% | 6.46% | 7.73% | 5.65% |